Episode 134 – Jordan Davidson returns

In this episode of The Cole Memo, I reconnect with Jordan Davidson, the Government Affairs Manager for Smart Approaches to Marijuana (SAM). SAM advocates for a “third-way” approach to cannabis policy; they oppose full legalization and commercialization. Jordan and Cole discuss legalization, a recent podcast from the New York Times, the shift from a five-part to a two-part federal test for medical efficacy, and the ongoing cultural/regulatory debates. The discussion also touches on potential future shifts in cannabis and drug policy.

  • Watch the episode on Patreon here
  • Watch the episode on Youtube here
  • Stream the episode on Soundcloud here
  • Stream the episode on Spotify here
  • Stream the episode on Apple Podcast here
  • Stream the episode on X here

Links mentioned during show

Screenshot from Jordan
  • This is the graphic that Jordan tried to show (see page 2)
  • https://casetext.com/case/alliance-for-cannabis-therapeutics-v-dea
    • Text from Jordan on above link: “The Final Order discards the earlier formulation and applies a new five-part test for determining whether a drug is in “currently accepted medical use”: (1) The drug’s chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. 57 Fed.Reg. at 10,506. None of these criteria is impossible for a Schedule I drug to meet; in fact, petitioners concede in their briefs that the new standard has corrected the flaws we identified in ACT.”

Published by

Leave a comment